These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 16156677)

  • 61. Drug selection and timing of initiation of treatment in early Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline.
    Lieberman A
    Neurology; 1992 Apr; 42(4 Suppl 4):37-40; discussion 41-8. PubMed ID: 1350073
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update.
    Chew ZX; Lim CL; Ng KY; Chye SM; Ling APK; Koh RY
    CNS Neurol Disord Drug Targets; 2023; 22(3):329-352. PubMed ID: 34970960
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Milestones in Parkinson's disease therapeutics.
    Rascol O; Lozano A; Stern M; Poewe W
    Mov Disord; 2011 May; 26(6):1072-82. PubMed ID: 21626552
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Advances in dopamine receptor agonists for the treatment of Parkinson's disease.
    Stocchi F; Torti M; Fossati C
    Expert Opin Pharmacother; 2016 Oct; 17(14):1889-902. PubMed ID: 27561098
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease.
    Ogawa N
    Neurology; 1998 Aug; 51(2 Suppl 2):S13-20. PubMed ID: 9711975
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).
    Sy MAC; Fernandez HH
    Neurotherapeutics; 2020 Oct; 17(4):1331-1338. PubMed ID: 32935299
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
    Haycox A; Armand C; Murteira S; Cochran J; François C
    Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The evolution of pharmacological treatment for Parkinson's disease.
    Almeida QJ; Hyson HC
    Recent Pat CNS Drug Discov; 2008 Jan; 3(1):50-4. PubMed ID: 18221241
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison chart: Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Dec; 62(1613):e1-e9. PubMed ID: 33647002
    [No Abstract]   [Full Text] [Related]  

  • 71. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.
    Tan YY; Jenner P; Chen SD
    J Parkinsons Dis; 2022; 12(2):477-493. PubMed ID: 34957948
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.
    Bezard E; Gray D; Kozak R; Leoni M; Combs C; Duvvuri S
    CNS Neurol Disord Drug Targets; 2024; 23(4):476-487. PubMed ID: 36999711
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
    Alborghetti M; Nicoletti F
    Curr Neuropharmacol; 2019; 17(9):861-873. PubMed ID: 30160213
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.
    Laurencin C; Danaila T; Broussolle E; Thobois S
    Rev Neurol (Paris); 2016; 172(8-9):512-523. PubMed ID: 27476416
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New dopaminergic therapies for PD motor complications.
    Larson D; Simuni T
    Neuropharmacology; 2022 Feb; 204():108869. PubMed ID: 34742740
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
    Kassubek J; Büttner T; Reichmann H; Riederer P; Schulz JB; Wüllner U; Csoti I
    Fortschr Neurol Psychiatr; 2010 Mar; 78 Suppl 1():S34-6. PubMed ID: 20195940
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Medical treatment of Parkinson disease.
    Stacy M
    Neurol Clin; 2009 Aug; 27(3):605-31, v. PubMed ID: 19555824
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
    Goetz CG; Poewe W; Rascol O; Sampaio C
    Mov Disord; 2005 May; 20(5):523-39. PubMed ID: 15818599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.